These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

262 related items for PubMed ID: 21206137

  • 21. Continued suppression of serum TSH level may be attributed to TSH receptor antibody activity as well as the severity of thyrotoxicosis and the time to recovery of thyroid hormone in treated euthyroid Graves' patients.
    Chung YJ, Lee BW, Kim JY, Jung JH, Min YK, Lee MS, Lee MK, Kim KW, Chung JH.
    Thyroid; 2006 Dec; 16(12):1251-7. PubMed ID: 17199435
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Two-day thionamide withdrawal prior to radioiodine uptake sufficiently increases uptake and does not exacerbate hyperthyroidism compared to 7-day withdrawal in Graves' disease.
    Kubota S, Ohye H, Yano G, Nishihara E, Kudo T, Ito M, Fukata S, Amino N, Kuma K, Miyauchi A.
    Endocr J; 2006 Oct; 53(5):603-7. PubMed ID: 16896267
    [Abstract] [Full Text] [Related]

  • 24. [Evaluation of the medical treatment of Graves' disease (GD)].
    Peixoto MC, Coeli CM, Vaisman M.
    Arq Bras Endocrinol Metabol; 2005 Jun; 49(3):410-9. PubMed ID: 16543996
    [Abstract] [Full Text] [Related]

  • 25. Predictive effect of antithyroid antibody for relapse of Graves' disease.
    Yoshizawa K, Aso K, Satoh M.
    Pediatr Int; 2022 Jan; 64(1):e14749. PubMed ID: 33884704
    [Abstract] [Full Text] [Related]

  • 26. Use of the 2nd generation TRAK human assay did not improve prediction of relapse after antithyroid medical therapy of Graves' disease.
    Zimmermann-Belsing T, Nygaard B, Rasmussen AK, Feldt-Rasmussen U.
    Eur J Endocrinol; 2002 Feb; 146(2):173-7. PubMed ID: 11834425
    [Abstract] [Full Text] [Related]

  • 27. Outcome of Graves' disease after antithyroid drug treatment in Taiwan.
    Wang PW, Liu RT, Tung SC, Chien WY, Lu YC, Chen CH, Kuo MC, Hsieh JR, Wang ST.
    J Formos Med Assoc; 1998 Sep; 97(9):619-25. PubMed ID: 9795530
    [Abstract] [Full Text] [Related]

  • 28. Comparison of standardized initial doses of two antithyroid drugs in the treatment of Graves' disease.
    Kallner G, Vitols S, Ljunggren JG.
    J Intern Med; 1996 Jun; 239(6):525-9. PubMed ID: 8656146
    [Abstract] [Full Text] [Related]

  • 29. Remission of Graves' hyperthyroidism and A/G polymorphism at position 49 in exon 1 of cytotoxic T lymphocyte-associated molecule-4 gene.
    Kinjo Y, Takasu N, Komiya I, Tomoyose T, Takara M, Kouki T, Shimajiri Y, Yabiku K, Yoshimura H.
    J Clin Endocrinol Metab; 2002 Jun; 87(6):2593-6. PubMed ID: 12050220
    [Abstract] [Full Text] [Related]

  • 30. The Second Antithyroid Drug Treatment Is Effective in Relapsed Graves' Disease Patients: A Median 11-Year Follow-Up Study.
    Kim YA, Cho SW, Choi HS, Moon S, Moon JH, Kim KW, Park DJ, Yi KH, Park YJ, Cho BY.
    Thyroid; 2017 Apr; 27(4):491-496. PubMed ID: 28001121
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. GENDER INFLUENCES THE CLINICAL PRESENTATION AND LONG-TERM OUTCOME OF GRAVES DISEASE.
    Magri F, Zerbini F, Gaiti M, Capelli V, Ragni A, Rotondi M, Chiovato L.
    Endocr Pract; 2016 Nov; 22(11):1336-1342. PubMed ID: 27540885
    [Abstract] [Full Text] [Related]

  • 34. Triiodothyronine-predominant Graves' disease in childhood: detection and therapeutic implications.
    Harvengt J, Boizeau P, Chevenne D, Zenaty D, Paulsen A, Simon D, Guilmin Crepon S, Alberti C, Carel JC, Léger J.
    Eur J Endocrinol; 2015 Jun; 172(6):715-23. PubMed ID: 25766047
    [Abstract] [Full Text] [Related]

  • 35. Is there a methimazole dose effect on remission rate in Graves' disease? Results from a long-term prospective study. The European Multicentre Trial Group of the Treatment of Hyperthyroidism with Antithyroid Drugs.
    Benker G, Reinwein D, Kahaly G, Tegler L, Alexander WD, Fassbinder J, Hirche H.
    Clin Endocrinol (Oxf); 1998 Oct; 49(4):451-7. PubMed ID: 9876342
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Long-term outcomes of anti-thyroid drug treatment in childhood-onset Graves' disease.
    Puttawong D, Mahachoklertwattana P, Numthavaj P, Woratanarat P, Pongratanakul S, Koad P, Poomthavorn P.
    Clin Endocrinol (Oxf); 2023 Jun; 98(6):823-831. PubMed ID: 36562146
    [Abstract] [Full Text] [Related]

  • 38. Long-Term Antithyroid Drug Treatment of Graves' Disease in Children and Adolescents: A 20-Year Single-Center Experience.
    Song A, Kim SJ, Kim MS, Kim J, Kim I, Bae GY, Seo E, Cho YS, Choi JY, Cho SY, Jin DK.
    Front Endocrinol (Lausanne); 2021 Jun; 12():687834. PubMed ID: 34194397
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.